ERDERA
European Rare Diseases Research Alliance
Basic Information
Description
The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in Rare Disease (RD) research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment. This Partnership will deliver a RD ecosystem that builds on the successes of previous programmes by supporting robust patient need-led research, developing new diagnostic methods and pathways, spearheading the digital transformational change connecting the dots between care, patient data and research, while ensuring strong alignment of strategies in RD research across countries and regions. Structuring goal-oriented public-private collaborations targeted at interventions all along the R&D value chain will ensure that the journey from knowledge to patient impact is expedited, thereby optimising EU innovation potential in RD. To support its ambition and missions ERDERA has been designed as a comprehensive and integrated ecosystem of which structure can be compared to an institute encompassing three main parts: (i) funding, (ii) internal (in house) Clinical Research Network that implements research activities targeting clinical trial readiness of RDs and accelerating diagnosis and translation of research discovery into improved patient care, and (iii) related supporting services (Data, Expertise, Education and Training) as well as an acceleration hub that serve external and internal RD community, all supported by all-embracing coordination and strategy and foundational (inter)national alignment.
H2020 Societal Challenges
HORIZON C1: Health
Research fields covered by the network
- Health
Is connected with
Joint Calls
Joint Call Title | Type | Launch Date | Deadline Pre-Proposal |
Deadline Full-Proposal |
Evaluation End Date |
---|---|---|---|---|---|
Joint Transnational Call (JTC) 2025 "Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation" | two-stages | 10/12/2024 | 13/02/2025 | 09/07/2025 | 30/12/2025 |